Baseline quality of life is associated with survival among people with advanced lung cancer
Affiliation
Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Dept Epidemiol & BiostatIssue Date
2020-05-15
Metadata
Show full item recordPublisher
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDCitation
Mario J. Trejo, Melanie L. Bell, Haryana M. Dhillon & Janette L. Vardy (2020) Baseline quality of life is associated with survival among people with advanced lung cancer, Journal of Psychosocial Oncology, DOI: 10.1080/07347332.2020.1765065Journal
JOURNAL OF PSYCHOSOCIAL ONCOLOGYRights
Copyright © 2020 Taylor & Francis Group, LLC.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Introduction: Lung cancer patients presenting with advanced cancer face low survival rates and a high symptom burden. There have been mixed findings for the association between survival and various patient reported outcomes (PROs). Methods: We used prospective data from 111 lung cancer patients with advanced stage III/IV disease to investigate the association of survival with PROs (European Organization for Research and Treatment of Cancer Core-30 and Lung Module). Cox proportional hazard models were used to examine the individual association between several PRO measures and survival. Results: Pain in chest and global quality of life (QoL) were found to have the strongest association with survival with a 20% increased hazard of death per 10% increase in pain in chest and 14% decrease in hazard of death per 10% increase in global QoL. Conclusion: Our results provide more evidence for the value of PRO data to inform clinical and patient decision-making.Note
12 month embargo; published online: 15 May 2020ISSN
0734-7332PubMed ID
32410506Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1080/07347332.2020.1765065
Scopus Count
Collections
Related articles
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
- Authors: Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
- Issue date: 2019 Dec
- Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
- Authors: Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS
- Issue date: 2018 Mar
- Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer.
- Authors: Friis RB, Hjøllund NH, Pappot H, Taarnhøj GA, Vestergaard JM, Skuladottir H
- Issue date: 2021 Mar
- Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
- Authors: Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Wei Z, Burke T, Pietanza MC, Rodríguez-Abreu D
- Issue date: 2020 Mar
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
- Authors: Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M
- Issue date: 2017 Dec